On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Ex ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

CCS has saved more than $10 million in taxpayer dollars through the use of PropheSee, its predictive analytics platform, ...

Glucotrack has announced the receipt of St Vincent’s Hospital Melbourne Human Research Ethics Committee’s (HREC) approval for ...

Learn how emerging technologies are enhancing patient engagement and treatment strategies in everyday practice.

President Trump’s second choice to serve as surgeon general has pitted some members of the Make America Great Again (MAGA) movement against allies of the Make America Healthy Again (MAHA) ...

While breastfeeding has many benefits for a mother and her baby, it has one major drawback: It's incredibly difficult to know how much milk the baby is consuming. To take the guesswork out of ...

Glucotrack (Nasdaq:GCTK) announced today that it received a hospital's ethical approval to study its continuous blood glucose ...

Ken Griffin, the founder of Citadel, is an influential albeit controversial figure in the investment industry.

The Swiss biotech company Roche on Monday announced plans for a $550 million expansion of its Indianapolis diagnostics and ...

Roche said Monday it plans to invest up to $550 million and add hundreds of jobs over the next five years at its Indianapolis ...